Evidence map›Paper›PMID 24534711›Full record

ArticlePostgraduate medical journal2014

Republished: Value of biomarkers in osteoarthritis: current status and perspectives.

M Lotz, J Martel-Pelletier, C Christiansen, M-L Brandi, O Bruyère, R Chapurlat, J Collette, C Cooper, G Giacovelli, J A Kanis and 11 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Postgraduate medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Correlations between metabolites in the synovial fluid and serum: A mouse injury study.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 10 countries.

M LotzDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, , La Jolla, California, USA.
J Martel-Pelletier
C Christiansen
M-L Brandi
O Bruyère
R Chapurlat
J Collette
C Cooper
G Giacovelli
J A Kanis
M A Karsdal
V Kraus
W F Lems
I Meulenbelt
J-P Pelletier
J-P Raynauld
S Reiter-Niesert
R Rizzoli
L J Sandell
W E Van Spil
J-Y Reginster
Université de Montréal · CAUniversity of Liège · BENordic Bioscience (Denmark) · DKAmsterdam UMC Location VUmc · NLDuke University · USFederal Institute for Drugs and Medical Devices · DEHôpital Edouard Herriot · FRLeiden University · NLScripps Research Institute · USUniversity Hospital of Geneva · CHUniversity Medical Center Utrecht · NLUniversity of Florence · ITUniversity of Oxford · GBUniversity of Sheffield · GBWashington University in St. Louis · US

Funding

Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1
6 · The paper itself

Abstract

Osteoarthritis affects the whole joint structure with progressive changes in cartilage, menisci, ligaments and subchondral bone, and synovial inflammation. Biomarkers are being developed to quantify joint remodelling and disease progression. This article was prepared following a working meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis convened to discuss the value of biochemical markers of matrix metabolism in drug development in osteoarthritis. The best candidates are generally molecules or molecular fragments present in cartilage, bone or synovium and may be specific to one type of joint tissue or common to them all. Many currently investigated biomarkers are associated with collagen metabolism in cartilage or bone, or aggrecan metabolism in cartilage. Other biomarkers are related to non-collagenous proteins, inflammation and/or fibrosis. Biomarkers in osteoarthritis can be categorised using the burden of disease, investigative, prognostic, efficacy of intervention, diagnostic and safety classification. There are a number of promising candidates, notably urinary C-terminal telopeptide of collagen type II and serum cartilage oligomeric protein, although none is sufficiently discriminating to differentiate between individual patients and controls (diagnostic) or between patients with different disease severities (burden of disease), predict prognosis in individuals with or without osteoarthritis (prognostic) or perform so consistently that it could function as a surrogate outcome in clinical trials (efficacy of intervention). Future avenues for research include exploration of underlying mechanisms of disease and development of new biomarkers; technological development; the 'omics' (genomics, metabolomics, proteomics and lipidomics); design of aggregate scores combining a panel of biomarkers and/or imaging markers into single diagnostic algorithms; and investigation into the relationship between biomarkers and prognosis.

Indexed as

InflammationOsteoarthritisOutcomes research

Identifiers

PMID24534711
PMCPMC3934547
OpenAlexW2090433287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.